<DOC>
	<DOCNO>NCT01147302</DOCNO>
	<brief_summary>The purpose research study evaluate safety , effect , pharmacology C1 Esterase Inhibitor ( human ) kidney transplant patient acute Antibody-Mediated Rejection ( AMR ) .</brief_summary>
	<brief_title>A Pilot Study Evaluate Use C1 Esterase Inhibitor ( Human ) Patients With Acute Antibody-Mediated Rejection</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Inclusion Criteria include : ≥18 year age . Weigh ≥50 kg . Donor specific antibody identify . Exclusion Criteria include : Any surgical medical condition could interfere administration study drug interpretation study result . History allergic reaction C1 Esterase Inhibitor blood product . Participation active dosing phase investigational drug study within 30 day prior dose study drug . Pregnancy lactation . Receipt experimental agent AMR within 1 month prior first dose study drug . Any infection cause hemodynamic compromise . History bleed clot abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>